Background. The importance of Mycoplasma genitalium in human immunodeficiency virus (HIV)-burdened sub-Saharan Africa is relatively unknown. We assessed the prevalence and explored determinants of this emerging sexually transmitted infection (STI) in high-risk women in Uganda.
from the urethra of 2 men with nongonococcal urethritis [5] . However, because the organism is difficult to culture, clinical and epidemiological studies only became possible following the development of sensitive and specific polymerase chain reaction (PCR) assays in the early 1990s [6, 7] . Studies investigating transmission of M. genitalium in couples and DNA sequence typing among sexual partners have concluded that the bacterium is sexually transmitted [8] [9] [10] [11] [12] .
M. genitalium is now considered a main cause of nonchlamydial nongonococcal urethritis (NCNGU) in men. A meta-analysis of 15 case-control studies reported that the prevalence of M. genitalium in men with NCNGU was 22%, compared with 6% in those without urethritis (pooled odds ratio [OR], 5.15; 95% confidence interval [CI], 3.6-7.4) [13] . Except for 1, all studies were conducted in high-income countries [14] . M. genitalium is also found in the female reproductive tract, and there is increasing evidence that this bacterium may cause cervicitis and urethritis and may be correlated with upper genital tract infections and its sequelae such as tubal factor infertility [15] [16] [17] [18] [19] [20] .
Sexually transmitted infections (STIs) are important risk factors for acquiring and transmitting HIV, and STI control is recognized worldwide as a priority in the prevention of HIV [21] . A recent meta-analysis of 19 cross-sectional studies showed a strong association between prevalent M. genitalium and HIV infection (summary OR, 2.01; 95% CI, 1.44-2.79), with a stronger effect in studies from sub-Saharan Africa (OR, 2.60; 95% CI, 2.17-3.11) [22] . More data on the importance and the epidemiological determinants of M. genitalium infection are needed from this HIV-burdened region in order to decide whether to include this emerging infection in the existing STI control strategies.
We investigated the epidemiology of M. genitalium infection in a cross-sectional study of women involved in high-risk sexual behavior in Kampala, Uganda. To our knowledge, this is the first study on M. genitalium infection in Uganda.
SUBJECTS AND METHODS

Study Population and Clinical Procedures
Our study was carried out in a recently established cohort of female sex workers in Kampala, Uganda. Here we report findings from the baseline survey of this cohort. The study setting and procedures have been described in detail elsewhere [23] . In brief, women engaged in commercial sex work and/or employed in entertainment facilities were recruited from red-light areas in southern Kampala and asked to participate in a cohort study. At baseline, women were interviewed about their sociodemographic characteristics, sexual risk behavior, alcohol use (using the CAGE questionnaire [24] ), intravaginal practices, reproductive health history and symptoms of STI. Blood was collected for HIV, herpes simplex virus type 2 (HSV-2) and syphilis testing. A speculum examination was performed and 2 endocervical specimens were collected using thin polyester (Dacron) swabs, 1 for the diagnosis of gonococcal and chlamydial infection and 1 to be stored for a later diagnosis of M. genitalium. One high vaginal swab was used to collect a specimen to be inoculated for culture of Trichomonas vaginalis, another to prepare a slide for the detection of bacterial vaginosis and of Candida infection. Women with symptomatic STIs were treated syndromically on the spot. Women with asymptomatic STIs were treated as soon as laboratory results became available. Because the diagnosis of M. genitalium was made on stored specimens up to 2 years after specimen collection, it was not possible to specifically treat for M. genitalium at the time of the survey.
Informed consent was obtained from all study participants. The study was approved by the Science and Ethics Committee of the Ugandan Virus Research Institute and by the Uganda National Committee for Science and Technology.
Laboratory Methods
For the detection of M. genitalium, the endocervical specimen was inserted in a buffer solution, using Cobas Amplicor specimen transport medium collection tubes (Roche Diagnostic Systems Inc., Branchburg, NJ). The samples were stored at 4°C until transport to the Medical Research Council (MRC)/UVRI laboratories in Entebbe within 12 hours of collection. The specimens were kept at 220°C until sample collection from all enrolled women was completed. They were then sent on dry ice to the Sexually Transmitted Infections Reference Centre at the National Institute for Communicable Diseases in Johannesburg, South Africa, for PCR testing. Real-time polymerase chain reaction for M. genitalium Genomic DNA was extracted from endocervical specimens using an X-tractor Gene automated DNA extractor (Corbett Life Science, Concorde, Australia). A total volume of 200 lL of each specimen was extracted and eluted to a final volume of 150 lL. For the first 200 DNA specimens, we performed an in-house real-time PCR for the qualitative detection of M. genitalium as well as a commercially available M. genitalium Real-TM assay (Sacace Biotechnologies, Como, Italy) [25] . The primers and probe for the in-house real-time PCR were designed at the Centers for Disease Control and Prevention and used to amplify the pdhD gene (coding for dihydrolipoamide dehydrogenase) in M. genitalium. The following primers and probe were used (nucleotides [nt] corresponding to the sequence with GenBank number L43967.2): forward primer, MG-041 (5#-CGG ATC AAG ACC AAG ATA CTT AAC TTT-3#; nt 329417-329391); reverse primer, MG-042 (5#-AGC TTG GGT TGA GTC AAT GAT AAA C-3#; nt 329336-329360); and a JOE-labeled probe, MG-048 (5#-[AminoC61JOE] CCA GGG TTT GAA AAA GCA CAA CAA GCT G [BHQ1a]-3#; nt 329389-329362). The primers were synthesized at the University of Cape Town, South Africa, and the probe was synthesized at Eurofins MWG Operon, Germany. The commercially available M. genitalium Real-TM assay targeted the DNA gyrase subunit B of M. genitalium. Due to a 100% concordance between the in-house and commercial M. genitalium assay results, we decided to test the remaining 825 specimens exclusively with the commercial assay. For both assays, the DNA was amplified using a real-time PCR platform (Rotor-Gene 3000/6000, Corbett Life Science) and detected using the specific fluorescent reporter dye probes of the 2 assays. The commercial assay included an internal control that served as an amplification control for each individually processed specimen and to identify possible inhibition reactions. M. genitalium G37 genomic DNA (ATCC 33530D) as well as the M. genitalium positive control included in the commercial assay were used as a positive control. The sequences of the primers and probes used in the commercial assay are proprietary. The potential crossreactivity and the analytical sensitivity of the kit, as well as the analytical specificity of the primers and probes, were tested and validated by Sacace Biotechnologies. Both assays were internally validated at the Sexually Transmitted Infections Reference Centre in Johannesburg, South Africa.
Laboratory testing for all other infections was performed at the central laboratories of the MRC/UVRI Uganda Unit in Entebbe. Neisseria gonorrhoeae and Chlamydia trachomatis were diagnosed on endocervical specimens using the Amplicor PCR test (Roche Diagnostic Systems Inc.). T. vaginalis was detected using a commercial culture kit (InPouch TV, BioMed Diagnostics, White City, OR). Microscopy on a Gram-stained vaginal specimen was done to diagnose bacterial vaginosis (using the Nugent criteria) and Candida infection. Serum specimens were processed to detect antibodies against HIV-1 (using Abbott Determine HIV-1/2 rapid assay with confirmation by 2 independent enzyme-linked immunosorbent assay [ 
Statistical Analysis
Data were double entered in Access and analyzed using STATA 11.0 (Stata Inc., College Station, TX). Factors independently associated with prevalent M. genitalium infection were analyzed using logistic regression to estimate OR and 95% CI. P values were obtained using likelihood ratio tests. The univariable associations of M. genitalium with sociodemographic and behavioral characteristics, reproductive health factors, and HIV and other STIs were assessed, and all factors associated with the outcome at P , .10 in univariable analyses were included in a multivariable model. The final model included only those factors that remained or became independently associated with M. genitalium infection (P , .05) after adjustment for all other factors.
RESULTS
Details of the study population have been published previously [23] . Briefly, 1027 women likely to be involved in high-risk sexual behavior in Kampala were enrolled between April 2008 and May 2009. The median age of the study population at baseline was 26 years (interquartile range, 22-30 years). The majority of women (70%) were formerly married (widowed, divorced, or separated) and 90% had received no more than primary school education. At enrollment, 96% reported engaging in sex work. Baseline HIV prevalence was 37%, more than 50% of the women were diagnosed with 1 or more other curable STIs, and 56% with bacterial vaginosis.
Among the 1025 women with results from endocervical samples, prevalence of M. genitalium was 14% (95% CI, 12%-17%), N. gonorrhoeae 13% (95% CI, 11%-15%), and C. trachomatis 9% (95% CI, 7%-11%). Among the 148 M. genitalium-infected women, 105 (71%) had M. genitalium infection only, while 26 (17%) were coinfected with N. gonorrhoeae, 12 (9%) with C. trachomatis, and 5 (3%) with both pathogens. Overall, 176 (17%) women were diagnosed with T. vaginalis, 36 (20%) of them being coinfected with M. genitalium. 
Univariable analysis
Prevalence of M. genitalium infection was higher in younger age groups, decreasing from 19% among those younger than 25 years to 7% among those 35 years or older (P-trend ,.01; Table 1 and Figure 1 ). There was little evidence that M. genitalium was associated with level of education or marital status. Women who had been pregnant but not had a live birth were at higher risk than those who had had at least 1 live birth (OR, 2.96; 95% CI, 1.46-5.99). Prevalence of M. genitalium infection was lower in women using injectable contraceptives (Depo-Provera) than in those not using any hormonal contraceptives (OR, 0.54; 95% CI, .33-.89); this was not the case for women using oral contraceptives. There was little evidence of an association with other behavioral factors, including number of lifetime partners, type of and condom use with last sexual partner, number of sexual partners in the last month, reported condom use with paying clients, alcohol use, and vaginal cleansing ( Table 1) .
Prevalence of M. genitalium infection was significantly higher among HIV-positive women than HIV-negative women (18% vs 12%; OR, 1.52; 95% CI, 1.07-2.17; Table 1 and Figure 1 ) and was also associated with N. gonorrhoeae, T. vaginalis, and bacterial vaginosis (P 5 .003, P 5 .02, and P 5 .03, respectively) but not with C. trachomatis. Women infected with Candida albicans had a lower prevalence of M. genitalium infection than women without (8% vs 15%; OR, 0.49; 95% CI, .24-.98). There was little evidence of association with HSV-2 infection or syphilis.
Multivariable analyses
On multivariable analyses, M. genitalium infection remained independently associated with younger age (P-trend ,.01) and use of injectable contraceptives (adjusted OR for use of DepoProvera 0.53; 95% CI, .32-.87; Table 1 ). M. genitalium prevalence also remained associated with reproductive history: women who got pregnant but never had a live birth were more likely to be infected with M. genitalium than women with at 
DISCUSSION
M. genitalium infection was detected at baseline in 14% of female sex workers enrolled in a cohort in Kampala, Uganda. The prevalence of M. genitalium infection was higher than the prevalence of gonorrhea (13%) and of chlamydial infection (9%). There are few comparable studies of M. genitalium in sub-Saharan Africa. The prevalence of M. genitalium, N. gonorrhoeae, and C. trachomatis among sex workers in West Africa was 26%, 16%, and 3%, respectively; in Kenya, prevalence was 16%, 8%, and 6%, respectively [17, 26] . A general population survey in Tanzania found that 3%, 2%, and 0.1% of women were infected with M. genitalium, C. trachomatis, and N. gonorrhoeae, respectively; and in Guinea-Bissau, the prevalence of M. genitalium among pregnant women was 6% [27, 28] . In high-income countries, the reported prevalence of M. genitalium is between 1% and 3% among women in the general population [29] [30] [31] [32] and between 4% and 8% among female STD clinic attendees [19, [33] [34] [35] , although higher infection rates were detected in sex workers, adolescents, and nonwhite women attending STD clinics (between 13% and 38%) [9, [36] [37] [38] [39] [40] . Most of the African studies, including ours, reported a higher prevalence of M. genitalium than of C. trachomatis infection, both in high-and low-risk women. This is in contrast with the studies in other regions where M. genitalium infection seems to be less prevalent than that of C. trachomatis. Furthermore, in the Kenyan sex workers cohort, the incidence of M. genitalium was also higher than that of C. trachomatis (23/100 and 14/100 person years, respectively) [26] .
A plausible explanation for the higher prevalence of M. genitalium in Africa is that the high prevalence of HIV infection across the continent increases the susceptibility of many individuals for M. genitalium, as suggested by the observations from the Kenyan cohort. However, it is likely that other factors also play a role. For example, the reservoir of latent persistent M. genitalium infections in men and women may be larger than expected. Because M. genitalium appears to have milder symptoms and signs compared with N. gonorrhoeae and C. trachomatis infections [16, 41] , even in symptomatic infections, women may less often seek care for M. genitalium than for other STIs. Furthermore, the doses of doxycycline and other antibiotics usually given as part of the syndromic treatment of nongonococcal urethritis, cervicitis, or pelvic inflammatory disease were found to be clinically effective but did not eradicate M. genitalium [42] [43] [44] [45] . Alternatively, M. genitalium may simply be more strongly associated with HIV than C. trachomatis.
It is currently not clear whether the association between HIV and M. genitalium infections is the consequence of a causal relationship whereby HIV infection increases the risk of M. genitalium acquisition or vice versa, whether it merely reflects the confounding effect of sexual risk behavior or whether a combination of these 3 possible mechanisms is at work, as is the case with some other STIs. A recent meta-analysis found a strong association between M. genitalium and HIV in cross-sectional studies, with an even stronger association in the subgroup analysis, which included studies from sub-Saharan Africa, although the authors did report that only a few studies had adjusted for confounding factors [22] . Longitudinal studies are urgently needed in order to better understand the temporal relationship between M. genitalium and HIV. To date, only 1 longitudinal study reported a significant association between prevalent HIV and acquisition of new M. genitalium infections [26] , and there are no published studies yet investigating whether prevalent M. genitalium infection enhances HIV acquisition or transmission.
Our study also assessed the sociodemographic, behavioral, and reproductive health characteristics associated with M. genitalium infection. The higher prevalence detected in younger women has also been reported in other studies [19, 32, 39] , and may indicate that some immunity could be acquired after initial or serial infection, as is the case with chlamydial infections. However, immunological studies are needed to confirm this theory.
There was no evidence for an association between high-risk sexual behavior and M. genitalium infection, which was consistent with results from the West African sex workers study [17] . This may be partly explained by the nature of this specific study population. Studies conducted in the general population [29, 30, 31, 32] or among women attending STD clinics [19, 39] , on the other hand, have reported contradicting results on the associations between inconsistent condom use, numbers of sexual partners, and the risk of M. genitalium infection. Our data showed that injectable contraceptives may be protective against M. genitalium infection and that oral contraceptives were not associated with the infection. Previous studies have reported conflicting results on the correlation between hormonal contraception and M. genitalium. Consequently, this relationship needs further exploration [39, 46] .
In our study, M. genitalium infection was associated with a history of having been pregnant but never having a live birth. Because women with current M. genitalium infection may have had other episodes of the infection before or may have had an untreated infection for a long time, it is plausible that past M. genitalium infections may have induced adverse pregnancy outcomes. To date, studies investigating the evidence for a relationship between M. genitalium and adverse pregnancy outcomes led to contradictory conclusions, and more research is needed [47] .
To our knowledge, this is the first study reporting results on M. genitalium using the commercial M. genitalium Sacace test. A 100% concordance was found between the in-house real-time PCR and this commercial M. genitalium assay. The advantages of using a commercial test kit are low setup costs, built-in quality control, prevalidation by the manufacturer, ease of use, reduced susceptibility to contamination, and reduced interlaboratory variability. The disadvantages are the high cost per test, possible need for additional instrumentation, and inability of laboratories to control any aspect of the assay design.
The present study has several limitations. First, the crosssectional design does not allow for investigation of temporal relationships between risk behavior, HIV/STI, and M. genitalium. Second, we had to rely on reported behaviors, which are sensitive to recall bias. Finally, our M. genitalium specimens were frozen for about 2 years until PCR testing in Johannesburg; this may have had a negative impact on the detection rate, as reported earlier in a Danish study [48] .
In conclusion, we found that infection with M. genitalium was more prevalent than N. gonorrhoeae and C. trachomatis infections in Ugandan sex workers, and that in terms of risk factors, M. genitalium infection seems to behave like C. trachomatis, which is in line with other studies [29, 39] . The association of this emerging STI with HIV in cross-sectional studies urgently calls for further research to explore the potential role of M. genitalium in the acquisition and transmission of HIV infection. This missing information is needed in order to decide whether the treatment of M. genitalium should be incorporated into existing syndromic management or not, especially in high-risk population groups.
Notes
